---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-014334"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:42:52.629194+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Palatin Q1 net loss $7.8M; obesity focus with BMT-801 topline Q1 2025; strategic review for non-obesity assets

## Summary
- Net loss $7.8M ($0.39/share) vs $5.2M a year ago; cash $2.4M at Sep 30, plus $2.5M deferred payment from Vyleesi sale received Nov 2024.
- Phase 2 BMT-801 (bremelanotide+tirzepatide) obesity study fully enrolled; topline results expected Q1 2025.
- Investment bank retained to explore strategic options for non-obesity programs including DED, UC, glaucoma, retina, and male ED.
- Novel MC4R long-acting peptide and oral small molecule IND enabling starts Q1 2025; Phase 1 targeted Q4 2025.
- DED program: FDA Type C meeting concluded; subject to funding, Phase 3 enrollment could start Q1 2025.

## SEC filing metadata
- accession: 0001654954-24-014334
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495424014334/0001654954-24-014334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495424014334/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-014334
- JSON: https://secwatch.observer/filing/0001654954-24-014334.json
- Plain text: https://secwatch.observer/filing/0001654954-24-014334.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.